Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
In the published Phase 2 research (Jastreboff et al., NEJM 2023), Retatrutide produced the largest body-weight outcomes of any single-compound incretin programme reported to date, distinguishing the triple-agonist class from dual agonists like Tirzepatide and single-target agonists like Semaglutide
It is not intended for use in humans or animals
Eat a light breakfast, hydrate well, and proceed with your day
Our products, within your choice, are formulated carefully for effectiveness, safety, and quality
Seek medical advice if fatigue is severe, worsening, or accompanied by chest pain, breathlessness, dehydration, persistent vomiting, or signs of hypoglycaemia in people with diabetes
US$ 27.67
US$ 28.01
US$ 25.51
